Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

	Related Links


	Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase III

Treatment

Active

18 and over

Pharmaceutical / Industry

A6181037
NCT00130897

Trial Description

Summary

To provide access to sunitinib to patients with metastatic renal cell carcinoma. People in this study will have been previously treated with cytokine therapy, e.g. interferon-alpha, but this is no longer effective.

Eligibility Criteria

Inclusion Criteria:

renal cell carcinoma that is not amendable to standard therapy with curative intent

Exclusion Criteria:

current treatment in another therapeutic clinical trial

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer CT.gov Call Center

Study Director

Pfizer Oncology Clinical Trial Information Service		Ph: 1-877-369-9753
		Email: PfizerCancerTrials@emergingmed.com

Trial Sites

Ecuador

Quito

Pfizer Investigational Site

India

Jaipur

Pfizer Investigational Site

New Delhi

Pfizer Investigational Site

Parel

Pfizer Investigational Site

Italy

Bergamo

Pfizer Investigational Site

Cattolica (RN)

Pfizer Investigational Site

Napoli

Pfizer Investigational Site

Padova

Pfizer Investigational Site

Pordenone

Pfizer Investigational Site

Rimini

Pfizer Investigational Site

Roma

Pfizer Investigational Site

Russia

Chelyabinsk

Pfizer Investigational Site

Moscow

Pfizer Investigational Site

Moscow 115 478

Pfizer Investigational Site

Obninsk

Pfizer Investigational Site

Serbia

Belgrade

Pfizer Investigational Site

Turkey

Istanbul

Pfizer Investigational Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00130897
Information obtained from ClinicalTrials.gov on July 16, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.